FDA DEVICE FACTS
Allix5
Clairity, Inc.
FDA-sourced product information for medical-device development research. Use the official FDA sources at the end of this page when the original public document wording is needed.医療機器開発の調査用に、FDA の公開情報から取った製品情報を示しています。公開文書の原文が必要なときは、このページの最後にある FDA の公式な出典をご覧ください。
Indications for use
The Clairity Allix5 software device is intended to generate a 5-year risk prediction of breast cancer based on a bilateral screening mammogram. Allix5 provides a prediction of the percentage probability that the individual will receive a diagnosis of breast cancer or develop breast cancer within the 5-year timeframe following the screening mammogram, through analysis of mammography features and characteristics. Eligible patients do not have a known breast cancer at presentation for their screening mammogram. Allix5 is not intended to diagnose or detect breast cancer, or to provide care recommendations. Allix5 is not intended to replace or to be used as the sole determinant for clinical decision-making. Allix5 output is intended to be considered after the radiologist has completed the interpretation of the screening mammogram. Allix5 analyzes full-field digital mammograms or directly acquired 2D images from Hologic Lorad Selenia and Selenia Dimensions Mammography Systems; it does not analyze synthetic-2D images.
Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。
OFFICIAL FDA SOURCES
FDA Record and Public Document Status
Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。